A placebo-controlled, double-blinded, randomized clinical trial of anti-TNF [tumour necrosis factor] chimeric monoclonal antibody (cA2) [infliximab] in patients with active rheumatoid arthritis despite methotrexate treatment

Trial Profile

A placebo-controlled, double-blinded, randomized clinical trial of anti-TNF [tumour necrosis factor] chimeric monoclonal antibody (cA2) [infliximab] in patients with active rheumatoid arthritis despite methotrexate treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ATTRACT
  • Sponsors Centocor
  • Most Recent Events

    • 01 Oct 2016 Results of post-hoc analyses on clinical remission rates using data from infliximab (ASPIRE,ATTRACT) and golimumab (GO-FORWARD) trials, published in the Arthritis and Rheumatology.
    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top